AbbVie Reports Third-Quarter 2013 Financial Results Wall Street Journal With partner Biogen Idec, AbbVie presented data from sub-analyses of the Phase 2 SELECT and SELECTION studies evaluating daclizumab. Daclizumab High-Yield Process (DAC HYP) is being developed as a once-monthly subcutaneous injection for ... |
